C.R. Bard, Inc. - Value Alert
Texas (September 3, 2013) Wax Ink has issued a Negative Investment Interest opinion for C. R. Bard, Inc. (NYSE: BCR) based on a recent baseline equity review which placed fair value between $59-$71.
The recent close of $114.87 is approximately 225% above the fair value buy target for the stock and approximately 58% above the fair value close target for the stock. The recent close is also 0% below analysts’ twelve-month $115.00 median price target for the stock.
The recent close represents a 17.5% increase in the one year price of the stock, while year-over year sales increased 2%, earnings increased 56%, and debt increased 20%.
The stock currently has a trailing twelve-month PE Ratio of 14, and a PEG Ratio of 1.7 basis estimated forward earnings growth of 8.0%.
In the past 52 weeks, share prices have moved between a high of $117.54 and a low of $93.9, placing equilibrium at $108.42.
With the recent close, the stock is trading 2% below the 52 week high, 18% above the 52 week low, and 6% above equilibrium.
The three-month average daily trading volume for the stock is approximately 535,000 shares.
C. R. Bard, Inc. designs, manufactures, packages, distributes, and sells medical, surgical, diagnostic, and patient care devices worldwide.
The company's listed competitors include B. Braun Melsungen AG, Boston Scientific Corporation,and Johnson and Johnson, Inc.
Financial information that may be contained herein, is based on the company's most recent annual SEC filing for year ending December 31, 2012.
All prices are per share unless otherwise noted.
Wax Ink currently has no investment position in any company mentioned in this alert.
For use by Accredited Investors as defined under Title 17, CFR §230.500, Regulation D.
Copyright © 2013 Wax Ink Wax Ink is a baseline equity research company not licensed or registered with any government agency